Novakand Pharma AB (FRA:3EE0) EBITDA Margin %: 0.00% (As of Dec. 2025)


What is Novakand Pharma AB EBITDA Margin %?

Novakand Pharma AB FRA:3EE0 EBITDA Margin % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Novakand Pharma AB ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Novakand Pharma AB's EBITDA for the three months ended in Dec. 2025 was €-0.46 Mil. Novakand Pharma AB's Revenue for the three months ended in Dec. 2025 was €0.00 Mil. Therefore, Novakand Pharma AB's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Novakand Pharma AB  (FRA:3EE0) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Novakand Pharma AB EBITDA Margin % Related Terms

Novakand Pharma AB EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Novakand Pharma AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novakand Pharma AB EBITDA Margin % Chart

Novakand Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,659.64 -6,957.35 0.00 0.00 0.00

Novakand Pharma AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:3EE0 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Novakand Pharma AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novakand Pharma AB EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novakand Pharma AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Novakand Pharma AB's EBITDA Margin % falls into.


Novakand Pharma AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Novakand Pharma AB's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-2.719/0
= %

Novakand Pharma AB's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.461/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Novakand Pharma AB (FRA:3EE0) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Novakand Pharma AB and its competitors. According to the industry distribution chart, Novakand Pharma AB ranks #999999 out of 944 companies in the Biotechnology industry.
Is Novakand Pharma AB's EBITDA Margin % too high?
Novakand Pharma AB's current EBITDA Margin % is 0.00%. Based on the distribution chart, Novakand Pharma AB ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Novakand Pharma AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Novakand Pharma AB ranks #999999 out of 944 companies for EBITDA Margin %. This places Novakand Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Novakand Pharma AB and its competitors. Novakand Pharma AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novakand Pharma AB stock overvalued right now?
Novakand Pharma AB (FRA:3EE0) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Novakand Pharma AB (FRA:3EE0), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novakand Pharma AB Business Description

Address Nanna Svarts vag 4, Solna, SWE, 171 65
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.